|
Half-Year ended 31 December 2012 |
Half-Year ended 31 December 2011 |
Reported |
At constant currency** |
|
|
Group revenue |
£252.2m |
£209.5m |
20.4% |
23.5% |
|
Underlying operating profit* |
£24.3m |
£16.2m |
50.1% |
60.2% |
|
Underlying profit before taxation* |
£21.0m |
£14.3m |
46.9% |
54.2% |
|
Operating profit |
£15.1m |
£11.0m |
37.3% |
|
|
Profit before tax |
£11.5m |
£8.9m |
29.2% |
|
|
|
|
|
|
|
|
Underlying earnings per share* |
18.03p |
14.57p† |
23.7% |
|
|
Earnings per share |
9.91p |
9.27p† |
6.9% |
|
|
Interim dividend per share |
4.34p |
3.77p† |
15.1% |
|
|
Net borrowings |
£102.0m |
£46.1m |
|
|
|
|
||||
|
Eurovet® integration in line with plan and delivering expected synergies |
||||
|
Solid growth across all trading segments |
||||
|
Own branded products delivering strong revenue growth |
||||
|
Two US product in-licensing deals completed |
||||
|
Increase in interim dividend of 15.1% |
